生物瓣与机械瓣主动脉瓣置换的长期医疗支出比较
该经济模拟模型基于文献流行病学与成本输入,估算生物瓣相对机械瓣主动脉瓣置换术后25年内的长期医疗支出差异。在45、55、65岁患者中,生物瓣置换的预期净节省分别为12266、15462、16008美元(2018年美元,95%CI均大于0)。敏感性分析假设死亡风险相等时,各年龄队列仍显示生物瓣的显著长期节省。
要点
- 生物瓣主动脉瓣置换在45、55、65岁患者中25年净节省分别为12266、15462、16008美元。
- 45岁生物瓣患者再手术费用差16201美元被抗凝监测节省26257美元抵消。
- 敏感性分析假设死亡风险相等时,三个年龄队列仍显示生物瓣显著长期节省。
核心结论
- 生物瓣相对机械瓣用于主动脉瓣置换与显著的长期医疗支出节省相关。
研究设计与样本
- 确定性及蒙特卡洛模拟模型,基于文献流行病学与成本输入,计算术后25年年度支出。
主要发现
- 45、55、65岁生物瓣患者25年净折扣节省分别为12266、15462、16008美元(2018年美元,95%CI均大于0)。
- 45岁生物瓣患者25年再手术费用差16201美元被同期抗凝监测节省26257美元抵消。
- 敏感性分析假设死亡风险相等时,三个年龄队列仍显示生物瓣显著长期节省。
关键数值与推荐
- 45岁患者生物瓣相对机械瓣25年净节省12266美元(2018年美元,95%CI大于0)。
- 55岁患者生物瓣相对机械瓣25年净节省15462美元(2018年美元,95%CI大于0)。
- 65岁患者生物瓣相对机械瓣25年净节省16008美元(2018年美元,95%CI大于0)。
- 45岁生物瓣患者25年再手术费用差16201美元,抗凝监测节省26257美元(2018年美元)。
临床怎么用
- 支付方、提供者及医疗系统可因生物瓣用于主动脉瓣置换的长期节省而获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines currently indicate the use of surgical aortic valve replacement (SAVR) to treat severe cases of aortic stenosis, particularly for low- to medium-risk patients. Although several studies have compared health outcomes of tissue and mechanical SAVR, this economic simulation model estimates the difference in long-term healthcare costs associated with tissue relative to mechanical SAVR. METHODS: The deterministic and Monte Carlo simulation models used literature-based epidemiologic and cost inputs to calculate annual expenditures related to SAVR for up to 25 years after initial surgery. A series of 3 cohort studies across different age groups provided the health outcome probabilities for tissue valve patients. Outcome probabilities for mechanical valve patients were based on relative risks reported in comparative meta-analyses or large cohort studies. RESULTS: Relative to mechanical SAVR the expected net discounted savings for a patient receiving tissue SAVR at ages 45, 55, and 65 years were $12,266, $15,462, and $16,008, respectively (based on 2018 US dollars) over a 25-year horizon (95% confidence intervals exceed $0). For a 45-year-old tissue SAVR patient, the estimated per-patient cost difference (relative to mechanical SAVR) of reoperation over 25 years ($16,201) were offset by expected savings on anticoagulation monitoring ($26,257) over the same period. In a sensitivity analysis in which mortality risk was assumed equal, significant long-term savings associated with tissue SAVR still accrued in each of the 3 age cohorts. CONCLUSIONS: Payers, providers, and the healthcare system may financially benefit from the use of tissue valves because significant savings were associated with the use of tissue valves relative to mechanical valves for SAVR.
引用
- Nguyen TC, Walker T, Gunnarsson C, et al. Long-term Healthcare Expenditures Over Time for Tissue and Mechanical Aortic Valve Replacement. Ann Thorac Surg. 2020. PMID: 33144108. doi:10.1016/j.athoracsur.2020.07.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。